The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Kuhl, Björn D ^a,b,d   Cheng, Vicky ^a,b   Donahue, Daniel A ^a,b   Sloan, Richard D ^a   Liang, Chen ^a,b   Wilkinson, John ^c   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c BIOTRON LIMITED   (Australia)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIT 225; MEMBRANE PROTEIN; N [5 (1 METHYL 1H PYRAZOL 4 YL) NAPTHALENE 2 CARBON YL] GUANIDINE; PROTEIN INHIBITOR; TETHERIN; UNCLASSIFIED DRUG; VIROPORIN; VIRUS PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BST2 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; GUANIDINE; GUANIDINE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LEUKOCYTE ANTIGEN; N (5 (1 METHYL 1H PYRAZOL 4 YL) NAPTHALENE 2 CARBONYL)GUANIDINE; N-(5-(1-METHYL-1H-PYRAZOL-4-YL)-NAPTHALENE-2-CARBONYL)GUANIDINE; PYRAZOLE DERIVATIVE; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL ACTIVITY; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CELL SURFACE; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TREATMENT RESPONSE; CELL LINE; CELL MEMBRANE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; VIRUS RELEASE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; ANTIGENS, CD; CELL LINE; CELL MEMBRANE; GENE EXPRESSION REGULATION; GPI-LINKED PROTEINS; GUANIDINE; GUANIDINES; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; PROTEIN STRUCTURE, TERTIARY; PYRAZOLES; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS RELEASE;

EID: 81055143760     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027660     Document Type: Article

References (54)

1. Anderson JL, Hope TJ, (2004) HIV accessory proteins and surviving the host cell. Current HIV/AIDS reports 1: 47-53.
2. Malim MH, Emerman M, (2008) HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3: 388-398.
3. Henriet S, Mercenne G, Bernacchi S, Paillart J-C, Marquet R, (2009) Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev 73: 211-232.
4. Niewiadomska AM, Yu X-F, (2009) Host restriction of HIV-1 by APOBEC3 and viral evasion through Vif. Curr Top Microbiol Immunol 339: 1-25.
5. Kuhl B, Cheng V, Wainberg M, Liang C, (2011) Tetherin and Its Viral Antagonists. Journal of Neuroimmune Pharmacology pp. 1-14.
6. Kirchhoff F, (2010) Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 8: 55-67.
7. Lim ES, Malik HS, Emerman M, (2011) The host antiviral protein Viperin restricts HIV-1 and other lentiviruses. Kesystone Symposia on HIV Evolution, Genomics and Pathogenesis: Abstract 307.
8. Fitzgerald KA, (2011) The interferon inducible gene: Viperin. J Interferon Cytokine Res 31: 131-135.
9. Langevin C, Maidou-Peindara P, Aas PA, Jacquot G, Otterlei M, et al. (2009) Human immunodeficiency virus type 1 Vpr modulates cellular expression of UNG2 via a negative transcriptional effect. Journal of Virology 83: 10256-10263.
10. Bour S, Strebel K, (2003) The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. Microbes and Infection 5: 1029-1039.
11. Cook GA, Zhang H, Park SH, Wang Y, Opella SJ, (2010) Comparative NMR studies demonstrate profound differences between two viroporins: p7 of HCV and Vpu of HIV-1. Biochim Biophys Acta.
12. Park SH, Mrse AA, Nevzorov AA, Mesleh MF, Oblatt-Montal M, et al. (2003) Three-dimensional structure of the channel-forming trans-membrane domain of virus protein "u" (Vpu) from HIV-1. J Mol Biol 333: 409-424.
13. Lopez CF, Montal M, Blasie JK, Klein ML, Moore PB, (2002) Molecular dynamics investigation of membrane-bound bundles of the channel-forming transmembrane domain of viral protein U from the human immunodeficiency virus HIV-1. Biophys J 83: 1259-1267.
14. Guatelli JC, (2009) Interactions of viral protein U (Vpu) with cellular factors. Curr Top Microbiol Immunol 339: 27-45.
15. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, et al. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3: 245-252.
16. Neil SJD, Zang T, Bieniasz PD, (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-430.
17. Jouvenet N, Neil SJD, Zhadina M, Zang T, Kratovac Z, et al. (2009) Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin. Journal of Virology 83: 1837-1844.
18. Blasius AL, Giurisato E, Cella M, Schreiber RD, Shaw AS, et al. (2006) Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol 177: 3260-3265.
19. Ishikawa J, Kaisho T, Tomizawa H, Lee BO, Kobune Y, et al. (1995) Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 26: 527-534.
20. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, et al. (2009) Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog 5: e1000450.
21. Miyagi E, Andrew AJ, Kao S, Strebel K, (2009) Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci USA 106: 2868-2873.
22. Vidal-Laliena M, Romero X, March S, Requena V, Petriz J, et al. (2005) Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. Cellular Immunology 236: 6-16.
23. Kuhl BD, Sloan RD, Donahue DA, Liang C, Wainberg MA, (2011) Vpu-mediated tetherin antagonism of ongoing HIV-1 infection in CD4+ T-cells is not directly related to the extent of tetherin cell surface downmodulation. Virology 417: 353-361.
24. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, et al. (2003) Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4: 694-709.
25. Habermann A, Krijnse Locker J, Oberwinkler H, Eckhardt M, Homann S, et al. (2010) CD317/Tetherin is Enriched in the HIV-1 Envelope and Downregulated from the Plasma Membrane upon Virus Infection. Journal of Virology pp. 1-33.
26. Perez-Caballero D, Zang T, Ebrahimi A, Mcnatt MW, Gregory DA, et al. (2009) Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139: 499-511.
27. Andrew AJ, Miyagi E, Strebel K, (2010) Differential Effects of Human Immunodeficiency Virus Type 1 Vpu on the Stability of BST-2/Tetherin. Journal of Virology pp. 1-37.
28. Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, et al. (2009) HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem.
29. Goffinet C, Allespach I, Homann S, Tervo H-M, Habermann A, et al. (2009) HIV-1 Antagonism of CD317 Is Species Specific and Involves Vpu-Mediated Proteasomal Degradation of the Restriction Factor. Cell Host and Microbe 5: 285-297.
30. Gupta RK, Hué S, Schaller T, Verschoor E, Pillay D, et al. (2009) Mutation of a Single Residue Renders Human Tetherin Resistant to HIV-1 Vpu-Mediated Depletion. PLoS Pathog 5: e1000443.
31. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, et al. (2009) Species-Specific Activity of HIV-1 Vpu and Positive Selection of Tetherin Transmembrane Domain Variants. PLoS Pathog 5: e1000300.
32. Rong L, Zhang J, Lu J, Pan Q, Lorgeoux R-P, et al. (2009) The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. Journal of Virology 83: 7536-7546.
33. Vigan R, Neil SJD, (2010) Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type-1 (HIV-1) Vpu protein. Journal of Virology 84: 12958-12970.
34. Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, et al. (2009) Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci USA 106: 20889-20894.
35. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, et al. (2009) Species-Specific Activity of SIV Nef and HIV-1 Vpu in Overcoming Restriction by Tetherin/BST2. PLoS Pathog 5: e1000429.
36. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, et al. (2009) Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6: 54-67.
37. Gonzalez ME, Carrasco L, (2003) Viroporins. FEBS Lett 552: 28-34.
38. Ewart GD, Mills K, Cox GB, Gage PW, (2002) Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Eur Biophys J 31: 26-35.
39. Ewart GD, Sutherland T, Gage PW, Cox GB, (1996) The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. Journal of Virology 70: 7108-7115.
40. Schubert U, Ferrer-Montiel AV, Oblatt-Montal M, Henklein P, Strebel K, et al. (1996) Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett 398: 12-18.
41. Park SH, Opella SJ, (2007) Conformational changes induced by a single amino acid substitution in the trans-membrane domain of Vpu: implications for HIV-1 susceptibility to channel blocking drugs. Protein Sci 16: 2205-2215.
42. Bolduan S, Votteler J, Lodermeyer V, Greiner T, Koppensteiner H, et al. (2011) Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317. Virology 416: 75-85.
43. Mehnert T, Routh A, Judge PJ, Lam YH, Fischer D, et al. (2008) Biophysical characterization of Vpu from HIV-1 suggests a channel-pore dualism. Proteins 70: 1488-1497.
44. Luscombe CA, Huang Z, Murray MG, Miller M, Wilkinson J, et al. (2010) A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Antiviral Res 86: 144-153.
45. Khoury G, Ewart G, Luscombe C, Miller M, Wilkinson J, (2010) Antiviral Efficacy of the Novel Compound BIT225 against HIV-1 Release from Human Macrophages. Antimicrobial Agents and Chemotherapy 54: 835-845.
46. Ewart GD, Nasr N, Naif H, Cox GB, Cunningham AL, et al. (2004) Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages. Antimicrobial Agents and Chemotherapy 48: 2325-2330.
47. Kuhl BD, Sloan RD, Donahue DA, Bar-Magen T, Liang C, et al. (2010) Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology 7: 115.
48. Aquaro S, Caliò R, Balzarini J, Bellocchi MC, Garaci E, et al. (2002) Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 55: 209-225.
49. Casartelli N, Sourisseau M, Feldmann J, Guivel-Benhassine F, Mallet A, et al. (2010) Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 6: e1000955.
50. Jolly C, Booth NJ, Neil SJD, (2010) Cell-cell spread of Human Immunodeficiency Virus type-1 overcomes tetherin/BST-2 mediated restriction in T cells. Journal of Virology.
51. Kuhl BD, Sloan RD, Donahue DA, Bar-Magen T, Liang C, et al. (2010) Neither ritonavir nor darunavir affect cell surface expression of tetherin or Vpu-mediated tetherin down-modulation. AIDS 24: 1970-1972.
52. Nara PL, Fischinger PJ, (1988) Quantitative infectivity assay for HIV-1 and-2. Nature 332: 469-470.
53. Schindler M, Münch J, Kirchhoff F, (2005) Human immunodeficiency virus type 1 inhibits DNA damage-triggered apoptosis by a Nef-independent mechanism. Journal of Virology 79: 5489-5498.
54. Oliveira M, Brenner BG, Wainberg MA, (2009) Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol Biol 485: 427-433.